SLDB
HealthcareSolid Biosciences Inc.
$5.33
$-0.12 (-2.20%)
Jan 5, 2026
Price History (1Y)
Analysis
Solid Biosciences Inc. is a biotechnology company within the healthcare sector, with approximately 100 employees and a market capitalization of $415.26 million. The company's financial health indicates significant losses, with net income totaling -$167.13 million over the trailing twelve months (TTM). The company's margins are also non-existent, with gross margin, operating margin, and profit margin all at 0.0%. Returns on equity and assets are also negative, standing at -86.8% and -43.7%, respectively. Additionally, the company has a significant amount of cash on hand, totaling $236.14 million, but also carries debt of $21.94 million. Solid Biosciences Inc.'s valuation metrics are unfavorable, with a forward price-to-earnings (P/E) ratio of -2.65 and an enterprise value to EBITDA (EV/EBITDA) ratio of -1.25. The company's price to book ratio is 1.90, but the absence of revenue growth and earnings growth data limits further analysis. Dividend information is not applicable as the dividend yield and payout ratio are both N/A.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Solid Biosciences Inc.
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It also develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $415.26M
- P/E Ratio
- N/A
- 52-Week High
- $7.37
- 52-Week Low
- $2.41
- Avg Volume
- 1.06M
- Beta
- 2.69
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 100